Permax

Roman name

Permax #

The composition and the form of

1 tablet contains pergolida nelfinavir 0.05, 0.25 or 1.0 mg; in blistere to 10 pcs. , in box 3, or 10 blisters.

Of drugs

Противопаркинсоничес кое. Does D_1- and D_2-dofaminoretseptora nigrostriarna system suppresses the secretion of prolactin.

Pharmacokinetics

Well drawn. In the blood of 90% is associated with malnutrition. Penetrates into the various organs and tissues (including in the central nervous system). Metabolised education 10 metabolites. Write largely through the kidneys.

Indications

Parkinson disease.

Pregnancy and lactation

Acceptable, but designate of pregnancy should only on the strict condition and under the supervision of a physician. Because of the possible excretion in breast milk to a breast-feeding or cancellation Permaxa (depending on the importance of treatment for a mother).

Contraindications

Гиперчувствительност ь (incl. to drugs LPV), a children's age (security is not known).

Side-Effects

Psoriasis, dizziness, hallucinations, sputannosti consciousness, drowsiness or insomnia; Diarrhoeal disorders (dry mouth, anorexia, nausea, vomiting, diarrhoea or constipation), respiratory disorders (despnoe, rhinitis). Very rarely, visual impairment and taste, pain (headache, in the thorax, in the neck, etc.), hypothetical or hypertension, fear, heart, anaemia, or lakopenia leucocytosis; Peripheral edema, changes in body mass, increased gout and other manifestations of metabolic, sweating, fever, skin rashes, itching, violations of the urogenital system, neirolepticeski malignant syndrome (fever, muscle rigidity, sputannosti consciousness, etc.).

Patient interaction

Do effects of Levodopa (including spin-off : is likely to create hallucinations, confusion, diskinezi). In conjunction with the release antagonists (neiroleptiki, fenotiazina, butirofenona, tioksantena and metoclopramide) may decline противопаркинсоничес кой activity.

Precautions

Be wary appoint patients with aritmiami, plevritom, plevralnam vpotom, plevralnam fibrosis, pericarditom, pericardialnam vpotom, retroperitonealnam fibrosis and other similar types of pathology (this category of patients must be carefully monitored clinical, which includes X-ray and laboratory studies), in combination with drugs, связывающимися significantly with the plasma protein-possible competition for protein and the increase in free fractions in the blood. With regard to the likely (especially at the beginning of therapy) suffer to start treatment with low doses, gradually increasing them. Lifting drug dose reduction or change regimens should be implemented in a gradual manner.

Dosing and Administration

Inside. Beginning with the 0.05 mg / day within two days, then dose gradually increased at 0.1-015 mg / day every third day for 12 days, followed by 0.25 mg (every third day) to achieve an optimal therapeutic effect. Daily dose is divided into three reception. Dosage appointed parallel леводопы / карбидопы can be reduced (up to the average daily dose леводопы-650 mg).

Storage conditions

table. : List B. The temperature of 15-30 ° C

Directory → Intermedianta → Dofaminomimetiki → Permax